Complement dependent cytotoxicity in chronic lymphocytic leukemia: Ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement

Leukemia and Lymphoma

Volumn 53, Issue 11, 2012, Pages 2218-2227

  Baig, Nisar A ^a   Taylor, Ronald P ^b   Lindorfer, Margaret A ^b   Church, Amy K ^a   Laplant, Betsy R ^c   Pavey, Emily S ^c   Nowakowski, Grzegorz S ^a   Zent, Clive S ^a  

^a Department of Medicine   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c MAYO CLINIC   (United States)

Author keywords

alemtuzumab; Chronic lymphocytic leukemia (CLL); complement dependent cytotoxicity; ofatumumab; resistance; rituximab

Indexed keywords

ALEMTUZUMAB; COMPLEMENT COMPONENT C3B; COMPLEMENT MEMBRANE ATTACK COMPLEX; OFATUMUMAB;

ADULT; AGED; ARTICLE; CANCER CELL; CELL SUBPOPULATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COMPLEMENT ACTIVATION; COMPLEMENT C3B; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED;

EID: 84867178829     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.681657     Document Type: Article

References (48)

1. Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2010:481-488.
2. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of f udarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-4088. (Pubitemid 46211313)
3. Kay NE, Geyer SM, Call TG, et al. Combination chemoimmuno-therapy with pentostatin, cyclophosphamide, and rituximab shows signif cant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007;109:405-411. (Pubitemid 46105933)
4. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to f udarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49-53. (Pubitemid 40053062)
5. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to f udarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-1174.
6. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in f udarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749-1755.
7. Zent CS, Chen JB, Kurten RC, et al. Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. Leuk Res 2004;28:495-507. (Pubitemid 38453062)
8. Golay J, Manganini M, Rambaldi A, et al. Effect of alemtuzumab on neoplastic B cells. Haematologica 2004;89:1476-1483.
9. Zent CS, Secreto CR, Laplant BR, et al. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk Res 2008;32:1849-1856.
10. Golay J, Lazzari M, Facchinetti V, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001;98:3383-3389.
11. Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol 2008;20:444-449.
12. Glennie MJ, French RR, Cragg MS, et al. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007;44:3823-3837. (Pubitemid 47332625)
13. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104:1793-1800. (Pubitemid 39202289)
14. Pawluczkowycz AW, Beurskens FJ, Beum P V, et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol 2009;183:749-758.
15. Clynes R, Towers T, Presta L, et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-446. (Pubitemid 30208162)
16. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-758. (Pubitemid 34525533)
17. Bowles JA, Weiner GJ. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods 2005;304:88-99. (Pubitemid 41262223)
18. Golay J, Cortiana C, Manganini M, et al. The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis. Haematologica 2006;91:322-330.
19. Bleeker WK, Munk ME, Mackus WJ, et al. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br J Haematol 2008;140:303-312.
20. Siders WM, Shields J, Garron C, et al. Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models. Leuk Lymphoma 2010;51:1293-1304.
21. Kohrt HE, Houot R, Goldstein MJ, et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2011;117:2423-2432.
22. Lundin J, Osterborg A, Brittinger G, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol 1998;16:3257-3563.
23. Rawstron AC, Kennedy B, Moreton P, et al. Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood 2004;103:2027-2031. (Pubitemid 38326216)
24. Zent CS, Call TG, Shanafelt TD, et al. Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab and rituximab Cancer 2008;113:2110-2118.
25. Beum P V, Lindorfer MA, Taylor RP. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. J Immunol 2008;181:2916-2924.
26. Kennedy AD, Beum PV, Solga MD, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004;172:3280-3288. (Pubitemid 38263720)
27. Bohana-Kashtan O, Ziporen L, Donin N, et al. Cell signals transduced by complement. Mol Immunol 2004;41:583-597. (Pubitemid 38824616)
28. Black SM, Schott ME, Batdorf BH, et al. IL-4 induces protection of vascular endothelial cells against killing by complement and melittin through lipid biosynthesis. Eur J Immunol 2010;40:803-812.
29. Beum PV, Lindorfer MA, Beurskens F, et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol 2008;181:822-832.
30. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362-371. (Pubitemid 43939148)
31. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 2008;111:5446-5456.
32. Morice WG, Kurtin PJ, Hodnefield JM, et al. Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: comparative analysis of flow cytometry and tissue biopsy in 252 patients. Mayo Clin Proc 2008;83:776-785. (Pubitemid 351948691)
33. Dewald GW, Brockman SR, Paternoster SF, et al. Chromosome anomalies detected by interphase f uorescence in situ hybridization: correlation with signif cant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 2003;121:287-295. (Pubitemid 36560596)
34. Jelinek DF, Tschumper RC, Geyer SM, et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol 2001;115:854-861. (Pubitemid 34042903)
35. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351:893-901. (Pubitemid 39096916)
36. Rossmann ED, Lenkei R, Lundin J, et al. Performance of calibration standards for antigen quantitation with flow cytometry in chronic lymphocytic leukemia. Cytometry B Clin Cytom 2007;72:450-457. (Pubitemid 350086251)
37. Brando B, Gohde W Jr, Scarpati B, et al. The "vanishing counting bead" phenomenon: ef ect on absolute CD34 + cell counting in phosphate-buf ered saline-diluted leukapheresis samples. Cytometry 2001;43:154-160.
38. Edberg JC, Tosic L, Wright EL, et al. Quantitative analyses of the relationship between C3 consumption, C3b capture, and immune adherence of complement-f xing antibody/DNA immune complexes. J Immunol 1988;141:4258-4265. (Pubitemid 19018214)
39. Harris CL, Lublin DM, Morgan BP. Ef cient generation of monoclonal antibodies for specif c protein domains using recombinant immunoglobulin fusion proteins: pitfalls and solutions. J Immunol Methods 2002;268:245-258. (Pubitemid 35246170)
40. Macor P, Tedesco F. Complement as ef ector system in cancer immunotherapy. Immunol Lett 2007;111:6-13. (Pubitemid 47017475)
41. Ricklin D, Hajishengallis G, Yang K, et al. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010;11:785-797.
42. Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003;101:3413-3415. (Pubitemid 36857922)
43. Nabhan C, Patton D, Gordon L, et al. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma 2004;45:2269-2273. (Pubitemid 39504321)
44. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed f udarabine: results of a large international study. Blood 2002;99:3554-3561. (Pubitemid 34534522)
45. Hu W, Ge X, You T, et al. Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. Cancer Res 2011;71:2298-2307.
46. Rutkowski MJ, Sughrue ME, Kane AJ, et al. Cancer and the complement cascade. Mol Cancer Res 2010;8:1453-1465.
47. Allendorf DJ, Yan J, Ross GD, et al. C5a-mediated leukotriene B4-amplif ed neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and beta-glucan. J Immunol 2005;174:7050-7056. (Pubitemid 40705670)
48. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916. (Pubitemid 32064784)